Annexon

ANNX

Market cap $996M

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for  Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart for the treatment of Guillain-Barré syndrome (GBS).

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P.

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

Annexon Inc. (ANNX) is still a "Buy" in my view, driven by progress in its c1q inhibitor pipeline for rare diseases. ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA discussions. Vonaprument, targeting dry age-related macular degeneration patients with geographic atrophy, is in phase 3 testing with topline data expected in 2nd half of 2026.

BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the closing of its previously announced underwritten public offering of 29,423,075 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 4,326,922 additional shares of common stock, at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase price of $2.599 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase price of $2.599 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. In addition, Annexon expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in  Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potential to Be the First Approved Vision Sparing Therapy for the Treatment of Eight Million GA Patients Worldwide ANX1502 Cold Agglutinin Disease (CAD) Proof of Concept Study Ongoing with Expected 2026 Completion; Potential to Be the Only Oral C1s Inhibitor for the Treatment of Multiple Neuroinflammatory Autoimmune Diseases Strong Financial Position and Execution Extends Operations into 2027, Through Several Important Milestones, Including Tanruprubart Global GBS Filings, Vonaprument Topline GA Phase 3 Data, and ANX1502 Autoimmune Proof of Concept Data BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress, announced key anticipated milestones and reported third quarter 2025 financial results.